These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 39137632)
1. Immunosuppressive MDSC and Treg signatures predict prognosis and therapeutic response in glioma. Yin B; Cai Y; Chen L; Li Z; Li X Int Immunopharmacol; 2024 Nov; 141():112922. PubMed ID: 39137632 [TBL] [Abstract][Full Text] [Related]
2. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives. Lin H; Liu C; Hu A; Zhang D; Yang H; Mao Y J Hematol Oncol; 2024 May; 17(1):31. PubMed ID: 38720342 [TBL] [Abstract][Full Text] [Related]
3. Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy. Kamran N; Kadiyala P; Saxena M; Candolfi M; Li Y; Moreno-Ayala MA; Raja N; Shah D; Lowenstein PR; Castro MG Mol Ther; 2017 Jan; 25(1):232-248. PubMed ID: 28129117 [TBL] [Abstract][Full Text] [Related]
4. Expression profiling of immune inhibitory Siglecs and their ligands in patients with glioma. Santegoets KCM; Gielen PR; Büll C; Schulte BM; Kers-Rebel ED; Küsters B; Bossman SAJFH; Ter Laan M; Wesseling P; Adema GJ Cancer Immunol Immunother; 2019 Jun; 68(6):937-949. PubMed ID: 30953118 [TBL] [Abstract][Full Text] [Related]
5. CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells. Chang AL; Miska J; Wainwright DA; Dey M; Rivetta CV; Yu D; Kanojia D; Pituch KC; Qiao J; Pytel P; Han Y; Wu M; Zhang L; Horbinski CM; Ahmed AU; Lesniak MS Cancer Res; 2016 Oct; 76(19):5671-5682. PubMed ID: 27530322 [TBL] [Abstract][Full Text] [Related]
6. Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer. Li F; Zhao Y; Wei L; Li S; Liu J Cancer Biol Ther; 2018 Aug; 19(8):695-705. PubMed ID: 29621426 [TBL] [Abstract][Full Text] [Related]
7. The Emerging Role of Myeloid-Derived Suppressor Cells in the Glioma Immune Suppressive Microenvironment. Mi Y; Guo N; Luan J; Cheng J; Hu Z; Jiang P; Jin W; Gao X Front Immunol; 2020; 11():737. PubMed ID: 32391020 [TBL] [Abstract][Full Text] [Related]
8. Ferroptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of glioma patients. Hu Y; Tu Z; Lei K; Huang K; Zhu X Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34726238 [TBL] [Abstract][Full Text] [Related]
9. Circadian Regulation Patterns With Distinct Immune Landscapes in Gliomas Aid in the Development of a Risk Model to Predict Prognosis and Therapeutic Response. Tian R; Li Y; Shu M Front Immunol; 2021; 12():797450. PubMed ID: 35069579 [TBL] [Abstract][Full Text] [Related]
10. Qu S; Liu J; Wang H Front Immunol; 2021; 12():648416. PubMed ID: 33889156 [TBL] [Abstract][Full Text] [Related]
11. Local Application of Autologous Platelet-Rich Fibrin Patch (PRF-P) Suppresses Regulatory T Cell Recruitment in a Murine Glioma Model. Panek WK; Pituch KC; Miska J; Kim JW; Rashidi A; Kanojia D; Lopez-Rosas A; Han Y; Yu D; Chang CL; Kane JR; Zhang P; Cordero A; Lesniak MS Mol Neurobiol; 2019 Jul; 56(7):5032-5040. PubMed ID: 30460615 [TBL] [Abstract][Full Text] [Related]
12. Functional assay to assess T-cell inhibitory properties of myeloid derived suppressor cells (MDSCs) isolated from the tumor microenvironment of murine glioma models. Alghamri MS; Kamran N; Kadiyala P; Lowenstein PR; Castro MG Methods Enzymol; 2020; 632():215-228. PubMed ID: 32000897 [TBL] [Abstract][Full Text] [Related]
13. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas. Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L Front Immunol; 2020; 11():603341. PubMed ID: 33363544 [TBL] [Abstract][Full Text] [Related]
14. Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2/αCD40 therapy. Weiss JM; Subleski JJ; Back T; Chen X; Watkins SK; Yagita H; Sayers TJ; Murphy WJ; Wiltrout RH J Immunol; 2014 Jun; 192(12):5821-9. PubMed ID: 24808361 [TBL] [Abstract][Full Text] [Related]
15. Prognostic Gene Expression Signature in Patients With Distinct Glioma Grades. Ait Ssi S; Chraa D; El Azhary K; Sahraoui S; Olive D; Badou A Front Immunol; 2021; 12():685213. PubMed ID: 34539626 [TBL] [Abstract][Full Text] [Related]
16. Glioma-derived CCL2 and CCL7 mediate migration of immune suppressive CCR2 Takacs GP; Kreiger CJ; Luo D; Tian G; Garcia JS; Deleyrolle LP; Mitchell DA; Harrison JK Front Immunol; 2022; 13():993444. PubMed ID: 36685592 [TBL] [Abstract][Full Text] [Related]
17. Immune Infiltrating Cells-Derived Risk Signature Based on Large-scale Analysis Defines Immune Landscape and Predicts Immunotherapy Responses in Glioma Tumor Microenvironment. Zhang N; Zhang H; Wang Z; Dai Z; Zhang X; Cheng Q; Liu Z Front Immunol; 2021; 12():691811. PubMed ID: 34489938 [TBL] [Abstract][Full Text] [Related]
18. Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function. Gielen PR; Schulte BM; Kers-Rebel ED; Verrijp K; Bossman SA; Ter Laan M; Wesseling P; Adema GJ Neuro Oncol; 2016 Sep; 18(9):1253-64. PubMed ID: 27006175 [TBL] [Abstract][Full Text] [Related]
19. Single cell RNA sequencing reveals differentiation related genes with drawing implications in predicting prognosis and immunotherapy response in gliomas. Zhou Z; Wei J; Yang Z; Bao Y; Jiang W; Lu B; Wang W; Li L Sci Rep; 2022 Feb; 12(1):1872. PubMed ID: 35115572 [TBL] [Abstract][Full Text] [Related]
20. Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma. Kang K; Xie F; Wu Y; Wang Z; Wang L; Long J; Lian X; Zhang F Int Immunopharmacol; 2021 Jul; 96():107610. PubMed ID: 33848908 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]